The role of HDACs in the proliferation/differentiation of OPCs and NPCs, as well as their alteration in AGC1 deficiency, was investigated in Oli-Neu cells and neurospheres treated with SAHA, a broad-spectrum HDAC inhibitor suppressing the family members in multiple HDAC classes (Xu et al., 2007) and approved by FDA for cancer therapy. This evidence concerns the gene HDAC9 and cancer.